Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Odetiglucan - HiberCell

Next Previous
Drug Profile

Odetiglucan - HiberCell

Alternative Names: B-glucan PGG; BTH-1677; Imprime; Imprime PGG; Soluble beta glucan - HiberCell

Latest Information Update: 24 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biothera
  • Developer Biothera; Dana-Farber Cancer Institute; HiberCell; Mayo Clinic; Merck Sharp & Dohme
  • Class Antibacterials; Antineoplastics; Beta Glucans
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Dectin 1 stimulants; Fc gamma receptor IIA modulators; Immunostimulants; Macrophage 1 antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Non-Hodgkin's lymphoma; Non-small cell lung cancer; Triple negative breast cancer
  • Phase I Liver metastases
  • Suspended Infections
  • No development reported Follicular lymphoma
  • Discontinued Adenocarcinoma; Chronic lymphocytic leukaemia; Colorectal cancer; Head and neck cancer; Malignant melanoma; Myelosuppression; Stem cell mobilisation

Most Recent Events

  • 24 Sep 2025 Discontinued - Phase-I for Adenocarcinoma (Metastatic disease, Combination therapy, Second-line therapy or greater) in USA (IV) (HiberCell pipeline, September 2025)
  • 24 Sep 2025 HiberCell plans a phase II investigator initiated clinical trial for liver metastases (Combination therapy) (HiberCell pipeline, September 2025)
  • 24 Jul 2025 Merck Sharp & Dohme in collaboration with Abramson Cancer Center at Penn Medicine plans a phase II trial for Adenocarcinoma (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (IV), in July 2025 (NCT07082439)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top